Status: Ongoing IND Studies
Highlights
- APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family
- Dual targeting of 4-1BB and OX40 provides synergistic co-stimulation of T cells with the potential to amplify the cytotoxic function of activated T cells and NK cells
- This can potentially lead to more robust anti-tumor responses
The Molecule
Potential advantages of APVO603 include:
- Broad Utility: Unlike chimeric antigen receptor T cell therapies (CAR-T) and bispecific CD3-based T cell engagers, APVO603 does not target a specific tumor antigen, thus allowing for broad potential therapeutic use for a number of different types of solid tumors
- Reduced Toxicity: Since 4-1BB and OX40 are costimulatory receptors that are primarily expressed only T cells that have previously been exposed to tumor antigen, we believe APVO603 has the potential to cause less toxicity compared to traditional CD3-based T cell engagers due to its selectivity
- Differentiation from 4-1BB Agonistic Monoclonal Antibodies: Because APVO603 contains an Fc that does not interact with Fc gamma receptors, it has the potential to be less toxic than monospecific 4-1BB antibodies
- Synergistic Activity: While the activation of either 4-1BB or OX40 alone stimulates anti-tumor T cell responses, as a dual agonist bispecific antibody APVO603 has the potential to produce a synergistic or amplified response resulting in more robust T cell response
View APVO603 Scientific Presentations Here:
https://aptevotherapeutics.gcs-web.com/presentations